Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Swedish Orphan Biovitrum (BIOVF) had Consolidated Net Income/Loss of $144.19M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$785.93M |
|
$144.19M |
|
$191.12M |
|
$594.81M |
|
$581.68M |
|
$204.25M |
|
$-20.46M |
|
$183.90M |
|
$183.90M |
|
$144.19M |
|
$144.19M |
|
|
Consolidated Net Income/Loss |
$144.19M |
$144.19M |
|
$204.25M |
|
$289.80M |
|
345.94M |
|
349.63M |
|
$0.42 |
|
$0.41 |
|
| Balance Sheet Financials | |
$1.67B |
|
$178.76M |
|
$7.22B |
|
$8.89B |
|
$2.37B |
|
$837.24M |
|
$2.10B |
|
$4.47B |
|
$4.42B |
|
$-2.35B |
|
$4.42B |
|
345.85M |
|
| Cash Flow Statement Financials | |
$123.18M |
|
$-956.81M |
|
$820.72M |
|
$113.89M |
|
$102.84M |
|
$-11.05M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.70 |
|
-- |
|
-- |
|
0.16 |
|
0.46 |
|
75.68% |
|
25.99% |
|
25.99% |
|
-- |
|
23.40% |
|
18.35% |
|
$122.86M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
0.34 |
|
0.77 |
|
116.22 |
|
3.26% |
|
-6.14% |
|
1.62% |
|
2.74% |
|
$12.77 |
|
$0.35 |
|
$0.35 |
|